Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1

Masanobu Kasai, Yoshiki Akatsuka, Nobuhiko Emi, Hirofumi Taji, Akio Kohno, Akihiro Abe, Mitsune Tanimoto, Yoshihisa Kodera, Hidehiko Saito

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We have established a pre-B acute lymphoblastic leukemia (ALL) cell line, NAGL-1, from the bone marrow of a patient diagnosed with pre-B ALL. The patient has been disease-free for the 4 years since allogeneic bone marrow transplantation from her HLA-genotypically identical sister. NAGL-1 showed a pre-B cell phenotype (CD19+, CD10+, cμ+, sμ-) mostly identical to freshly isolated leukemic cells from the patient. This cell line strongly expressed HLA class I and HLA-DR molecules, as well as the costimulatory molecules CD54, CD40, and CD86. Cytotoxic T-lymphocyte (CTL) lines were generated by stimulating the donor-derived peripheral blood mononuclear cells with either irradiated leukemic cells or NAGL-1. Both CTL lines showed specific lysis against NAGL-1 in 51 Cr release assays. Lytic activity was partially inhibited by anti-CD8 and anti-HLA class I monoclonal antibodies. Treatment of NAGL-1 with TNF-α increased its susceptibility to the CTL line. One CD8 + T cell clone derived from the CTL line killed both the patient phytohemagglutinin (PHA) blasts and NAGL-1 but not the donor PHA blasts, suggesting that the clone recognized the patient-specific minor antigen presented on both PHA blasts and NAGL-1. Utilization of leukemic cell lines could be a useful model for the development of CTL lines and clones for immuno-logical study and potential immunotherapy.

Original languageEnglish
Pages (from-to)112-118
Number of pages7
JournalInternational Journal of Hematology
Volume69
Issue number2
Publication statusPublished - 01-12-1999
Externally publishedYes

Fingerprint

B-Lymphoid Precursor Cells
Cytotoxic T-Lymphocytes
Lymphocytes
Transplants
Phytohemagglutinins
Cell Line
Clone Cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Homologous Transplantation
HLA-DR Antigens
Bone Marrow Transplantation
Immunotherapy
Siblings
Blood Cells
Bone Marrow
Monoclonal Antibodies
Tissue Donors
T-Lymphocytes
Phenotype
Antigens

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Kasai, M., Akatsuka, Y., Emi, N., Taji, H., Kohno, A., Abe, A., ... Saito, H. (1999). Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1. International Journal of Hematology, 69(2), 112-118.
Kasai, Masanobu ; Akatsuka, Yoshiki ; Emi, Nobuhiko ; Taji, Hirofumi ; Kohno, Akio ; Abe, Akihiro ; Tanimoto, Mitsune ; Kodera, Yoshihisa ; Saito, Hidehiko. / Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1. In: International Journal of Hematology. 1999 ; Vol. 69, No. 2. pp. 112-118.
@article{435530ef015c4643bc8e3acd32220b5f,
title = "Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1",
abstract = "We have established a pre-B acute lymphoblastic leukemia (ALL) cell line, NAGL-1, from the bone marrow of a patient diagnosed with pre-B ALL. The patient has been disease-free for the 4 years since allogeneic bone marrow transplantation from her HLA-genotypically identical sister. NAGL-1 showed a pre-B cell phenotype (CD19+, CD10+, cμ+, sμ-) mostly identical to freshly isolated leukemic cells from the patient. This cell line strongly expressed HLA class I and HLA-DR molecules, as well as the costimulatory molecules CD54, CD40, and CD86. Cytotoxic T-lymphocyte (CTL) lines were generated by stimulating the donor-derived peripheral blood mononuclear cells with either irradiated leukemic cells or NAGL-1. Both CTL lines showed specific lysis against NAGL-1 in 51 Cr release assays. Lytic activity was partially inhibited by anti-CD8 and anti-HLA class I monoclonal antibodies. Treatment of NAGL-1 with TNF-α increased its susceptibility to the CTL line. One CD8 + T cell clone derived from the CTL line killed both the patient phytohemagglutinin (PHA) blasts and NAGL-1 but not the donor PHA blasts, suggesting that the clone recognized the patient-specific minor antigen presented on both PHA blasts and NAGL-1. Utilization of leukemic cell lines could be a useful model for the development of CTL lines and clones for immuno-logical study and potential immunotherapy.",
author = "Masanobu Kasai and Yoshiki Akatsuka and Nobuhiko Emi and Hirofumi Taji and Akio Kohno and Akihiro Abe and Mitsune Tanimoto and Yoshihisa Kodera and Hidehiko Saito",
year = "1999",
month = "12",
day = "1",
language = "English",
volume = "69",
pages = "112--118",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "2",

}

Kasai, M, Akatsuka, Y, Emi, N, Taji, H, Kohno, A, Abe, A, Tanimoto, M, Kodera, Y & Saito, H 1999, 'Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1', International Journal of Hematology, vol. 69, no. 2, pp. 112-118.

Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1. / Kasai, Masanobu; Akatsuka, Yoshiki; Emi, Nobuhiko; Taji, Hirofumi; Kohno, Akio; Abe, Akihiro; Tanimoto, Mitsune; Kodera, Yoshihisa; Saito, Hidehiko.

In: International Journal of Hematology, Vol. 69, No. 2, 01.12.1999, p. 112-118.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1

AU - Kasai, Masanobu

AU - Akatsuka, Yoshiki

AU - Emi, Nobuhiko

AU - Taji, Hirofumi

AU - Kohno, Akio

AU - Abe, Akihiro

AU - Tanimoto, Mitsune

AU - Kodera, Yoshihisa

AU - Saito, Hidehiko

PY - 1999/12/1

Y1 - 1999/12/1

N2 - We have established a pre-B acute lymphoblastic leukemia (ALL) cell line, NAGL-1, from the bone marrow of a patient diagnosed with pre-B ALL. The patient has been disease-free for the 4 years since allogeneic bone marrow transplantation from her HLA-genotypically identical sister. NAGL-1 showed a pre-B cell phenotype (CD19+, CD10+, cμ+, sμ-) mostly identical to freshly isolated leukemic cells from the patient. This cell line strongly expressed HLA class I and HLA-DR molecules, as well as the costimulatory molecules CD54, CD40, and CD86. Cytotoxic T-lymphocyte (CTL) lines were generated by stimulating the donor-derived peripheral blood mononuclear cells with either irradiated leukemic cells or NAGL-1. Both CTL lines showed specific lysis against NAGL-1 in 51 Cr release assays. Lytic activity was partially inhibited by anti-CD8 and anti-HLA class I monoclonal antibodies. Treatment of NAGL-1 with TNF-α increased its susceptibility to the CTL line. One CD8 + T cell clone derived from the CTL line killed both the patient phytohemagglutinin (PHA) blasts and NAGL-1 but not the donor PHA blasts, suggesting that the clone recognized the patient-specific minor antigen presented on both PHA blasts and NAGL-1. Utilization of leukemic cell lines could be a useful model for the development of CTL lines and clones for immuno-logical study and potential immunotherapy.

AB - We have established a pre-B acute lymphoblastic leukemia (ALL) cell line, NAGL-1, from the bone marrow of a patient diagnosed with pre-B ALL. The patient has been disease-free for the 4 years since allogeneic bone marrow transplantation from her HLA-genotypically identical sister. NAGL-1 showed a pre-B cell phenotype (CD19+, CD10+, cμ+, sμ-) mostly identical to freshly isolated leukemic cells from the patient. This cell line strongly expressed HLA class I and HLA-DR molecules, as well as the costimulatory molecules CD54, CD40, and CD86. Cytotoxic T-lymphocyte (CTL) lines were generated by stimulating the donor-derived peripheral blood mononuclear cells with either irradiated leukemic cells or NAGL-1. Both CTL lines showed specific lysis against NAGL-1 in 51 Cr release assays. Lytic activity was partially inhibited by anti-CD8 and anti-HLA class I monoclonal antibodies. Treatment of NAGL-1 with TNF-α increased its susceptibility to the CTL line. One CD8 + T cell clone derived from the CTL line killed both the patient phytohemagglutinin (PHA) blasts and NAGL-1 but not the donor PHA blasts, suggesting that the clone recognized the patient-specific minor antigen presented on both PHA blasts and NAGL-1. Utilization of leukemic cell lines could be a useful model for the development of CTL lines and clones for immuno-logical study and potential immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0033073470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033073470&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 112

EP - 118

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 2

ER -